Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets
Clinical trial NCT04006704 · COMPLETED
Trial details
- NCT number
- NCT04006704
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-10
- Primary completion
- 2020-03-06
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.